- Home
- FLC vs KPTI Comparison
FLC vs KPTI Comparison
Compare FLC & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | KPTI |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.0M | 148.0M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | FLC | KPTI |
|---|---|---|
| Price | $17.60 | $6.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | 37.8K | ★ 424.7K |
| Earning Date | 01-01-0001 | 02-18-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $142,530,000.00 |
| Revenue This Year | N/A | $3.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.62 | $3.51 |
| 52 Week High | $15.45 | $10.75 |
Technical Indicators
Market Signals| Indicator | FLC | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 46.37 |
| Support Level | $17.50 | $5.88 |
| Resistance Level | $17.68 | $7.09 |
| Average True Range (ATR) | 0.11 | 0.68 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 66.67 | 24.88 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.